Targets › XE
2 programs from 2 companies in 4 trials: 2 Phase 2, 2 Phase 1; Other, Respiratory, Oncology; next expected readout Jan 2027.
Open in Phaseline: the race on XE, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Sean Fain | Xenon MRI MRI contrast agent using hyperpolarized xenon to assess regional lung ventilation and perf | XE | Phase 2 | Imaging Techniques | Jan 2027 |
| University of Virginia | Hyperpolarized Xenon-129 MRI Inhaled hyperpolarized xenon-129 contrast agent for lung ventilation imaging via MRI | XE | Phase 2 | Lung Transplant Rejection; Chronic Obstructive Pulmonary Disease; E-Cig Use | Mar 2029 |
Lung Transplant Rejection (1) Chronic Obstructive Pulmonary Disease (1) E-Cig Use (1) Imaging Techniques (1)
small molecule (2)
University of Virginia (1) Sean Fain (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.